Cerbios-Pharma showcasing a new line of Food Supplements based on proprietary SF68® probiotic at Vitafoods Europe

news-releasesCERBIOS-PHARMA SA
April 17th 2023

Cerbios-Pharma SA, a pharmaceutical company headquartered in Lugano, Switzerland, with more than 40 years of experience in the pharmaceutical industry, will be a prominent presence at the leading nutraceuticals industry event, the Vitafoods Europe conference in Geneva.

From its stand at Booth Q49 at the Palexpo Center, Cerbios will showcase its innovative portfolio of products based on its well-proven proprietary probiotic strain SF68®. These include therapies for acne & seborrheic dermatitis, dyslipidemias & obesity, and irritable bowel syndrome (IBS).

Nutraceutical force

The Cerbios team at Vitafoods Europe will be led by Sales & Marketing Manager Dr. Federico Bianchi, who said Cerbios-Pharma had become a significant force in the nutraceuticals industry.

“This highly prestigious event provides us with an excellent platform to inform the industry about the strengths of this impressive portfolio of finished formulations, all based on the efficacy of SF68® whose pharmacological properties and safety profile have been extensively confirmed in many clinical trials,” Dr. Bianchi noted.

“While SF68 has been an undisputed market leader in Switzerland and Austria as an antidiarrheal microorganism for many years, we have now been able to extend it to unconventional uses, such as skin complaints, obesity and IBS, again with claims well supported by scientific evidence,” he added.

About Cerbios-Pharma

Cerbios is a privately held company located in Lugano, Switzerland, specialized in different areas:  manufacturing pharmaceutical active ingredients (Drug Substances), offering CDMO services and manufacturing Finished Pharmaceutical Forms based on its proprietary probiotic strain SF68®.

Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies.

Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders.

Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and a new Food Supplements line for the management of:

  • ACNE & Seborrheic dermatitis
  • Dyslipidemias, obesity and metabolic syndrome
  • IBS (Food for Special Medical Purposes)
  • Immune response booster.

Learn more at: https://cerbios.ch

About Vitafoods Europe 2023

The Vitafoods™ Europe conference is a leading event for the global nutraceuticals industry, attracting close to 15,000 suppliers and thousands of visitors from more than 130 countries. Visitors are predominantly drawn from the dietary supplements, pharmaceuticals, natural and herbal medicines, food, health foods and functional food and drinks sectors.

Vitafoods Europe 2023 is a three-day event opening May 9 at the Palexpo center at Le Grand Saconnex near Geneva, Switzerland, accompanied by an online platform that stays live from May 1 to May 12.

The conference will feature more than 80 speakers exploring industry priorities that include market trends, regulatory complexities, packaging and labelling challenges in four main topic areas: Ingredients & Raw Materials, Finished Products, Contract Manufacturing & Private Label, and Services & Equipment.

The event is organized by Informa Markets, with more information available at: www.vitafoods.eu.com


Click on Cerbios-Pharma at Vitafoods Europe 2023 for further information.
Click on Cerbios-Pharma SA to see event exhibitor profile.
Click on New Flora & Pharmaceutical probiotics based on SF68 to learn more.


CERBIOS-PHARMA Company Brochure

Cerbios-Pharma showcasing a new line of Food Supplements based on proprietary SF68® probiotic at Vitafoods Europe
Cerbios-Pharma showcasing a new line of Food Supplements based on proprietary SF68® probiotic at Vitafoods Europe